Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $1.8 million.

  • Lifecore Biomedical, Inc. \De\'s Share-based Compensation rose 1357.95% to $1.8 million in Q2 2025 from the same period last year, while for May 2025 it was $10.2 million, marking a year-over-year increase of 6381.23%. This contributed to the annual value of $10.2 million for FY2025, which is 6381.23% up from last year.
  • Latest data reveals that Lifecore Biomedical, Inc. \De\ reported Share-based Compensation of $1.8 million as of Q2 2025, which was up 1357.95% from $2.6 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Share-based Compensation peaked at $3.4 million during Q4 2024, and registered a low of $620000.0 during Q3 2021.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Share-based Compensation had a median value of $1.0 million in 2022 and averaged $1.3 million.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Share-based Compensation plummeted by 3049.33% in 2021 and then surged by 11382.37% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Share-based Compensation (Quarter) stood at $686000.0 in 2021, then surged by 61.52% to $1.1 million in 2022, then soared by 42.33% to $1.6 million in 2023, then skyrocketed by 113.82% to $3.4 million in 2024, then tumbled by 46.17% to $1.8 million in 2025.
  • Its Share-based Compensation was $1.8 million in Q2 2025, compared to $2.6 million in Q1 2025 and $3.4 million in Q4 2024.